WHO Drug Information Vol. 15, No. 3 & 4, 2001
(2001; 76 pages) View the PDF document
Table of Contents
View the documentWHO Drug Information
Open this folder and view contentsPersonal Perspectives
Open this folder and view contentsReports on Individual Drugs
Open this folder and view contentsQuality Assurance Issues
Close this folderCurrent Topics
View the documentAntimicrobials in animal feed: a threat to human use
View the documentDeclaration of Helsinki and placebo-controlled clinical trials
Open this folder and view contentsGeneral Information
Open this folder and view contentsRegulatory and Safety Matters*
Open this folder and view contentsATC/DDD Classification
Open this folder and view contentsRegulatory Information
View the documentRecommended International Nonproprietary Names (rec. Inn): List 46
View the documentSelected WHO Publications of Related Interest
 

Declaration of Helsinki and placebo-controlled clinical trials

The Declaration of Helsinki is acknowledged as the cornerstone of research ethics. Its current guidelines on the ethical use of placebo-controlled trials has caused some confusion in the research world and for this reason the Council of the World Medical Association has decided to publish a note of clarification on their interpretation. This step was necessitated by the cancellation of the Fifty-third World Medical Association General Assembly, which was due to take place during October 2001. The Assembly is the only body with the authority to adopt formal changes to the Declaration. The full text of the note reads as follows.

The WMA is concerned that paragraph 29 of the revised Declaration of Helsinki (October 2000) has led to diverse interpretations and possible confusion. It thereby affirms its position that extreme care must be taken in making use of a placebo-controlled trial and that in general this methodology should only be used in the absence of existing proven therapy. However, a placebo-controlled trial may be ethically acceptable, even if proven therapy is available, under the following circumstances:

• Where for compelling and scientifically sound methodological reasons its use is necessary to determine the efficacy or safety of a prophylactic, diagnostic or therapeutical methods, or

• Where a prophylactic, diagnostic or therapeutical method is being investigated for a minor condition and the patients who receive placebo will not be subject to any additional risk of serious or irreversible harm.

All other provisions of the Declaration of Helsinki must be adhered to, especially the need for appropriate ethical and scientific review.

At the same meeting, the WMA decided to appoint a panel of advisers, representative of all stakeholders in research, to assist the WMA in its continuing review of the Declaration of Helsinki.

Reference: http://www.wma.net/e/home.html

 

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: July 10, 2017